New Study: OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024

Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behcet's disease (BD). In 2014, there were 137,603 and 82,454 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan), respectively. Untreated, the organs and tissues affected by the damaged blood vessels do not get enough blood, which can lead to organ or tissue damage, or even death. J&J's Remicade was the first biologic in the vasculitis market, approved for BD in Japan in 2007. Other biologics approved for vasculitis include AbbVie's Humira for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM. Several unmet needs still remain such as the development of drugs with improved safety and efficacy for use in both the induction and maintenance treatment settings . GlobalData expects the launch of six drugs during the 2014 to 2024 forecast period along with increased diagnosed patient numbers will drive the vasculitis market.

Full Report Details at
- http://www.fastmr.com/prod/1151669_opportunityanalyzer.aspx?afid=301

Highlights

Key Questions Answered

* How large an impact will biosimilars have on the vasculitis market? What do vasculitis specialists and key opinion leaders across the 7MM think about the evolving treatment landscape?
* What opportunities remain in the market for new product entrants?
* With six drug launches, five of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect the sales of induction and maintenance therapies?
* According to KOLs, what are the most important unmet needs in vasculitis? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
* What industry developments are likely to affect sales of the top-selling vasculitis drugs in the markets researched? Which is the largest growth market globally?

Key Findings

* Biosimilars are expected to change the landscape for vasculitis and create pricing pressure in the vasculitis market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.
* Sales of immunosuppressants are expected to decline due to the introduction of novel biologics and small molecules to treat vasculitis.
* Several unmet needs are expected to remain after the forecast period, as all pipeline drugs are in development as induction therapies and maintenance therapies are lagging.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update
- OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecast to 2024
- OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024